UP TO DAY POSSIBILITIES OF ATRIAL FIBRILLATION PREVENTION
<p>Inhibitors of the renin-angiotensin-aldosterone system, statins, and possibly , ω-3 polyunsaturated fatty acids may influence the incidence of atrial fibrillation (AF), and can be used to prevent it. In recent medical literature, this approach is referred to as upstream treatment. The resul...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Stolichnaya Izdatelskaya Kompaniya
2015-12-01
|
Series: | Racionalʹnaâ Farmakoterapiâ v Kardiologii |
Subjects: | |
Online Access: | http://www.rpcardio.ru/jour/article/view/501 |
id |
doaj-3f2f3caecf624deaaff7a092a0b463e4 |
---|---|
record_format |
Article |
spelling |
doaj-3f2f3caecf624deaaff7a092a0b463e42020-11-24T22:37:15ZengStolichnaya Izdatelskaya KompaniyaRacionalʹnaâ Farmakoterapiâ v Kardiologii1819-64462225-36532015-12-018456156810.1234/1819-6446-2012-4-561-568501UP TO DAY POSSIBILITIES OF ATRIAL FIBRILLATION PREVENTIONE. A. Protasova0N. V. Furman1O. V. Reshet'ko2Саратовский научно-исследовательский институт кардиологииСаратовский научно-исследовательский институт кардиологииСаратовский государственный медицинский университет им. В.И. Разумовского<p>Inhibitors of the renin-angiotensin-aldosterone system, statins, and possibly , ω-3 polyunsaturated fatty acids may influence the incidence of atrial fibrillation (AF), and can be used to prevent it. In recent medical literature, this approach is referred to as upstream treatment. The results of experiments and clinical studies show that the use of these drugs may be useful for AF primary prevention in certain categories of patients. Nevertheless, there are currently no sufficient evidences to justify these recommendations and apply them to a wider range of patients with AF risk factors. Thus, it is reasonable to continue studies on both primary and secondary AF prevention.</p>http://www.rpcardio.ru/jour/article/view/501фибрилляция предсердийпрофилактика |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
E. A. Protasova N. V. Furman O. V. Reshet'ko |
spellingShingle |
E. A. Protasova N. V. Furman O. V. Reshet'ko UP TO DAY POSSIBILITIES OF ATRIAL FIBRILLATION PREVENTION Racionalʹnaâ Farmakoterapiâ v Kardiologii фибрилляция предсердий профилактика |
author_facet |
E. A. Protasova N. V. Furman O. V. Reshet'ko |
author_sort |
E. A. Protasova |
title |
UP TO DAY POSSIBILITIES OF ATRIAL FIBRILLATION PREVENTION |
title_short |
UP TO DAY POSSIBILITIES OF ATRIAL FIBRILLATION PREVENTION |
title_full |
UP TO DAY POSSIBILITIES OF ATRIAL FIBRILLATION PREVENTION |
title_fullStr |
UP TO DAY POSSIBILITIES OF ATRIAL FIBRILLATION PREVENTION |
title_full_unstemmed |
UP TO DAY POSSIBILITIES OF ATRIAL FIBRILLATION PREVENTION |
title_sort |
up to day possibilities of atrial fibrillation prevention |
publisher |
Stolichnaya Izdatelskaya Kompaniya |
series |
Racionalʹnaâ Farmakoterapiâ v Kardiologii |
issn |
1819-6446 2225-3653 |
publishDate |
2015-12-01 |
description |
<p>Inhibitors of the renin-angiotensin-aldosterone system, statins, and possibly , ω-3 polyunsaturated fatty acids may influence the incidence of atrial fibrillation (AF), and can be used to prevent it. In recent medical literature, this approach is referred to as upstream treatment. The results of experiments and clinical studies show that the use of these drugs may be useful for AF primary prevention in certain categories of patients. Nevertheless, there are currently no sufficient evidences to justify these recommendations and apply them to a wider range of patients with AF risk factors. Thus, it is reasonable to continue studies on both primary and secondary AF prevention.</p> |
topic |
фибрилляция предсердий профилактика |
url |
http://www.rpcardio.ru/jour/article/view/501 |
work_keys_str_mv |
AT eaprotasova uptodaypossibilitiesofatrialfibrillationprevention AT nvfurman uptodaypossibilitiesofatrialfibrillationprevention AT ovreshetko uptodaypossibilitiesofatrialfibrillationprevention |
_version_ |
1725717974006890496 |